FDA’s Plan B Plan Fails To Appease Von Eschenbach Blockers
Executive Summary
FDA's recent request to meet with Barr Labs about the proposed OTC switch of Plan B has not ensured smooth sailing for the confirmation process of Acting FDA Commissioner Andrew von Eschenbach
You may also be interested in...
Plan B Approval Clears The Way For Von Eschenbach Confirmation
FDA's decision to approve the emergency contraceptive Plan B for over-the-counter sale to women age 18 and older opens the door to a vote on FDA Acting Commissioner Andrew von Eschenbach's nomination to the permanent post
Plan B Approval Clears The Way For Von Eschenbach Confirmation
FDA's decision to approve the emergency contraceptive Plan B for over-the-counter sale to women age 18 and older opens the door to a vote on FDA Acting Commissioner Andrew von Eschenbach's nomination to the permanent post
Von Eschenbach’s FDA Will Be A “Facilitating Agency,” Nominee Says
FDA Commissioner-nominee Andrew von Eschenbach plans to use the agency as an engine to help drive product development